Providence CFO to step down
Greg Hoffman will retire in June after almost a decade at the nonprofit Catholic health system. His retirement comes as Providence attempts to execute a financial turnaround plan.
Greg Hoffman will retire in June after almost a decade at the nonprofit Catholic health system. His retirement comes as Providence attempts to execute a financial turnaround plan.
Gavin Wood spent 20 years at J&J, culminating in a spell as company group chairman for the medtech business in Europe, the Middle East and Africa.
Coloplast names former J&J executive Gavin Wood as CEO Read More »
The assistant launched for members of the technology giant’s One Medical primary care chain in January. Now, the tool will be available to all U.S. customers.
Amazon expands access to health-focused AI assistant Read More »
Among the unreported adverse events potentially linked to Ozempic are two deaths and one case of “completed suicide,” according to an FDA inspection report.
Novo Hit With FDA Warning Letter for Unreported Ozempic Safety Signals Read More »
Orforglipron, Eli Lilly’s oral obesity drug, is under FDA review with a decision expected in April. The pharma has also filed for marketing authorization for the pill in China.
Lilly Pumps $3B Into China to Boost Supply of Weight-Loss Pill Read More »
Capricor Therapeutics’ deramiocel was rejected in July 2025, potentially caught between Nicole Verdun, a former top biologics regulator at the FDA, and Vinay Prasad, director of the Center for Biologics Evaluation and Research.
Capricor Shares Rise as FDA Lifts Duchenne Cell Therapy Rejection Read More »
Unos restos fósiles de 95 millones de años de antigüedad encontrados en la Patagonia argentina reescriben la historia evolutiva de un enigmático grupo de dinosaurios. Se trata de restos excepcionalmente bien preservados y completos de un diminuto dinosaurio carnívoro …
Rare disease biotech stocks pop on the news that Vinay Prasad, the FDA’s chief biologics regulator, will depart the FDA at the end of April; Sen. Ron Johnson launches an investigation into recent rare disease drug rejections; and Roche and Zealand’s amylin analog fails to match investor expectations—and Eli Lilly’s rival candidate—in a mid-stage trial.
The U.S. Senate has a plan to improve drug development for rare disease patients. The exit of controversial CBER chief Vinay Prasad will help clear the path.
Rare Disease Patients Can’t Wait for Regulatory Process Read More »
Un nuevo estudio demuestra que las células endoteliales, que recubren todos los vasos sanguíneos del organismo, desempeñan un papel mucho más activo de lo que se pensaba en la regulación del metabolismo y del envejecimiento. El estudio es obra de un equipo …